Background Chemotherapeutic agents, such as cisplatin, are known to induce a persistent
polyneuropathy. The mechanisms underlying the development of this pain are complex, and …

Paclitaxel is a first-line chemotherapeutic with the major dose-limiting side effect of painful
neuropathy. Previous preclinical studies indicate mitochondrial dysfunction and oxidative …

Repeated administration of peroxisome proliferator–activated receptor gamma (PPARg)
agonists reduces neuropathic pain-like behavior and associated changes in glial activation …

Oxaliplatin (OXA) is a common chemotherapy drug and exhibits clinical activity in several
cancer types. Its anticancer clinical effect is frequently accompanied by neurotoxicity. The …

Background Oxaliplatin, the third-generation platinum compound, has evolved as one of the
most important therapeutic agents in colorectal cancer chemotherapy. The main limiting …

Painful neuropathy is the major dose-limiting side effect of paclitaxel chemotherapy.
Mitochondrial dysfunction and adenosine triphosphate (ATP) deficit have previously been …

Aims Oxaliplatin is a key drug in the treatment of colorectal cancer, but it causes acute and
chronic peripheral neuropathies. We previously reported that repeated administration of …

Background: Oxaliplatin chemotherapy induced neuropathy is a dose related cumulative
toxicity that manifests as tingling, numbness, and chronic pain, compromising the quality of …

Chemotherapy-induced peripheral neuropathy (CIPN) is the major dose-limiting side-effect
of many front-line anticancer drugs. This study was designed to establish and …

Oxaliplatin is a platinum-based anticancer drug used to treat metastatic colorectal, breast,
and lung cancers. While oxaliplatin kills cancer cells effectively, it exhibits several side …